Table 4:
Correlation of miR-21 expression with clinicopathological features (x̅±sd)
| Groups | n (n=68) | miR-21 | t/F | P |
|---|---|---|---|---|
| Age (yr) | 0.353 | 0.725 | ||
| ≤40 | 30 | 4.71±1.44 | ||
| >40 | 38 | 4.83±1.35 | ||
| Body weight (kg) | 0.050 | 0.957 | ||
| ≤60 | 20 | 4.76±1.31 | ||
| >60 | 48 | 4.78±1.41 | ||
| Height (cm) | 0.246 | 0.807 | ||
| ≤160 | 31 | 4.81±1.36 | ||
| >160 | 37 | 4.73±1.32 | ||
| Clinical staging | 10.710 | <0.001 | ||
| Stage I | 22 | 4.01±1.31 | ||
| Stage II | 21 | 4.52±1.42 | ||
| Stage III | 25 | 5.78±1.34 | ||
| Lymph node metastasis | 2.130 | 0.037 | ||
| Yes | 37 | 5.13±1.37 | ||
| No | 31 | 4.41±1.41 | ||
| Differentiation | 2.339 | 0.022 | ||
| Poorly differentiated | 30 | 5.18±1.39 | ||
| Highly differentiated | 38 | 4.36±1.47 |